ArticleJournal of cheminformatics2025
APBIO: bioactive profiling of air pollutants through inferred bioactivity signatures and prediction of novel target interactions.
Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioactivity-driven prediction of antibacterial synergy using machine learning models.PLoS computational biology · 2026Article
- Correction: APBIO: bioactive profiling of air pollutants through inferred bioactivity signatures and prediction of novel target interactions.Journal of cheminformatics · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
More sophisticated representations of compounds attempt to incorporate not only information on the structure and physicochemical properties of molecules, but also knowledge about their biological traits, leading to the so-called bioactivity profile. The bioactive profiling of air pollutants is challenging and crucial, as their biological activity and toxicological effects have not been deeply investigated yet, and further exploration could shed light on the impact of air pollution on complex disorders. Therefore, a biological signature that simultaneously captures the chemistry and the biology of small molecules may be beneficial in predicting the behaviour of such ligands towards a protein target. Moreover, the interactivity between biological entities can be represented through combined feature vectors that can be given as input to a machine learning (ML) model to capture the underlying interaction. To this end, we propose a chemogenomic approach, called Air Pollutant Bioactivity (APBIO), which integrates compound bioactivity signatures and target sequence descriptors to train ML classifiers subsequently used to predict potential compound-target interactions (CTIs). We report the performances of the proposed methodology and, via external validation sets, demonstrate its outperformance compared to existing molecular representations in terms of model generalizability. We have also developed a publicly available Streamlit application for APBIO at ap-bio.streamlit.app, allowing users to predict associations between investigated compounds and protein targets.Scientific contributionWe derived ex novo bioactivity signatures for air pollutant molecules to capture their biological behaviour and associations with protein targets. The proposed chemogenomic methodology enables the prediction of novel CTIs for known or similar compounds and targets through well-established and efficient ML models, deepening our insight into the molecular interactions and mechanisms that may have a deleterious impact on human biological systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.